ЛЕРКАНИДИПИН ПРИ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ

Lercanidipine is a lipophilic dihydropyridine (DHP) calcium antagonist (CA) with a long receptor half-life. The slow action onset prevents reflex tachycardia, typical for other DHP CAs. Taken once a day, lercanidipine provides an even, sustained antihypertensive action. Its antihypertensive activity is equivalent to many other medications, and lercanidipine is effective as monotherapy or in combination. Its effectiveness has been demonstrated in various age groups, as well as in patients with additional risk factors. Lercanidipine is well tolerated, and adverse effects, typical for DHP CAs, are observed early in the treatment. Lercanidipine therapy is associated with lower incidence of pedal oedema and subsequent treatment withdrawal, compared to amlodipine and nifedipine GITS. In preclinical and preliminary clinical trials, lercanidipine demonstrated anti-atherosclerotic effects and left ventricular hypertrophy reduction. Its effectiveness and tolerability profile make lercanidipine a suitable choice for treating various clinical groups of patients with arterial hypertension.